Compare Alexandria Real Estate Equities Inc (ARE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Zoetis Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.29 (market cap $8.28B), while Zoetis Inc trades at $73.5 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 3.8× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| ARE | ZTS | |
|---|---|---|
Market Cap | $8.28B | $31.14B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $156.76 |
52-Week Low | $40.41 | $71.91 |
Enterprise Value | $20.98B | $38.70B |
Dividend Yield | 5.99% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.01, down 0.7% on the day, with a bearish technical signal and mixed fundamentals. The stock shows negative profitability with a net income margin of -37.12% and ROE of -6.29% for 2025, though it maintains a strong gross margin of 67.28%. Recent Q2 2026 earnings missed EPS expectations but beat on FFO, with leasing momentum improving. The current price is near the analyst low target of $48.00, with support at $47 and resistance at $49.
Outlook remains cautious due to persistent net losses and high debt, but a 36% analyst buy rating and recent institutional acquisitions suggest potential recovery if leasing trends and FFO guidance hold. Key risks include occupancy pressures, legal scrutiny, and macroeconomic sensitivity. The stock presents a speculative opportunity for value investors betting on a real estate turnaround.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
